TABLE 3.
Pro-apoptotic effect of BBR on the three cancers in vitro.
| Disease | Cell lines | Dose of BBR | Duration | Detail | Ref. |
|---|---|---|---|---|---|
| Breast cancer | MCF-7 cells | 1, 10 μM | 24, 48, 72 h | Cell proliferation inhibition, cell cycle arrest | Sakaguchi et al. (2020) |
| 100 μM | 72 h | Cell death | |||
| MCF-7 cells, MDA-MB-231 cells | 50, 100 μM | 24, 48 h | Apoptosis | Sun et al. (2019) | |
| MDA-MB-468 cells | 3, 6, 12 μM | 1, 2, 3, 4 days | Cell proliferation inhibition | Lin et al. (2019) | |
| MDA-MB-231 cells | 6.25, 12.5, 25 μM | ||||
| MDA-MB-453 cells | 2.5, 5, 10 μM | ||||
| BT-549 cells | 5, 10, and 20 μM | ||||
| HCC70 cells | 0.5, 1 µM | 120, 144 h | Apoptosis | El Khalki et al. (2020) | |
| BT-20 cells | |||||
| MDA-MB-468 cells | |||||
| MDA-MB-231 cells | 5 μg/ml | 48 h | Apoptosis | Zhao et al. (2017) | |
| MDA-MB-231 cells | 2.5–100 μg/ml | 48 h | Cell proliferation, growth and metastasis inhibition | Yao et al. (2019) | |
| MDA-MB-231 cells | 25 μmol/L | 48 h | Cell migration inhibition | Zhao and Zhang. (2020) | |
| ZR-75-30 cells | 0.78, 1.56, 3.12 µM | 48 h | Cell proliferation, migration inhibition | Ma et al. (2017) | |
| MDA-MB-231 cells | 20, 40, 80, 160 μmol/L | 48, 72 h | DNA breaks | Gao et al. (2019) | |
| Multidrug-resistant MCF-7 cells | 80, 160, 320 µM | 24, 48, 72 h | Apoptosis | Pan et al. (2017) | |
| MCF-7 cells, MDA-MB-231 cells | 100 µM | 48,72 h | Apoptosis | Jabbarzadeh Kaboli et al. (2019) | |
| MCF-7 cells, MDA-MB-231 cells | 20, 40, 80 µM | 24, 48 h | Cell cycle arrest | Tak et al. (2019) | |
| Dox resistant MCF-7 cells | 50, 100, 150, 200 µM | 48 h | Cell growth inhibition | Wang et al. (2020) | |
| Lung cancer | H1975 cells, A549 cells | 6.25, 12.5, 25, 50 and 100 μM | 24, 48, 72 h | Cell growth, migration and invasion inhibition, cell cycle arrest | Zheng et al. (2018a) |
| H1299 cells, A549 cells | 20, 100 μM | 48 h | Apoptosis | Fu et al. (2013) | |
| A549 cells | 3.15, 6.25, 12.5, 25 μM | 48 h | Apoptosis | Kumar et al. (2020) | |
| 40, 80,120 μM | 48 h | Apoptosis | Chen et al. (2019) | ||
| H1975 cells, H1650 cells | 0.78125–12.5 μM | 24 h | Cell growth inhibition | Fan et al. (2018) | |
| A549 cells | 20–200 μM | 24, 36, and 48 h. | Apoptosis | Kalaiarasi et al. (2016) | |
| H1975 cells | 25 μmol/L | 24 h | Apoptosis | Zheng et al. (2020) | |
| Liver cancer | HepG2 cells | 5 μg/ml | 4 days | Limits DOX-exacerbated HCC repopulation | Zhang et al. (2019b) |
| Hep3B cells, BEL-7404 cells | 50, 75, 100, 125 μM | 12, 24, 48 h | Cell proliferation inhibition | Zhang et al. (2019c) | |
| HepG2 cells | 10, 50, and 100 μg/ml | 24, 48, 72 h | Cell proliferation inhibition, apoptosis | Li et al. (2017) | |
| HepG2 cells | 50, 100 μM | 18, 24 h | Apoptosis | Saxena et al. (2018) | |
| Huh-7.HCVrep cells | 100 μM | 24, 48 h | Apoptosis | Tai et al. (2020) | |
| MHCC97L Cells, PLC/PRF/5 cells | 7.8125–1,000 μM | 24 h | Apoptosis | Guo et al. (2020) | |
| HepG2 cells, Hep3B cells, SNU-182 cells | 10, 20, 50, 100 µM | 72 h | Cell proliferation inhibition | Chuang et al. (2017) | |
| HepG2 cells | 100 μM | 24 h | Cell growth inhibition | Chen et al. (2016) | |
| HepG2 cells | 50, 100 μM | 6 h | Cell invasion and metastasis inhibition | Wang et al. (2016) | |
| HepG2 cells | 3.125 μM | 7 days | Chemotherapy-induced apoptosis promoted migration inhibition | Zhao et al. (2020) | |
| Huh-7 cells, HepG2 cells | 30 μM | 14 days | Cell cycle arrest | Li et al. (2018a) | |
| Huh7 cells | 50 μM | 72 h | Apoptosis | Vishnoi et al. (2021) | |
| MHCC97-H cells, HepG2 cells | 50, 100, 200 μM | 24 h | Apoptosis | Song et al. (2019b) |
Note: Huh-7.HCVrep cells: AB12-A2 Huh-7 replicon cells carrying the HCV genotype 1b subgenomic RNA.